Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-15-transpresenting Wilms tumor 1-targeting dendritic cell vaccine
- Development stage
- Phase 2
- Lead developer
- Antwerp University Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
This is an autologous cellular immunotherapy developed by Antwerp University Hospital. It consists of monocyte-derived dendritic cells (DCs) that are electroporated with mRNA encoding the Wilms tumor 1 (WT1) protein and mRNA encoding a fusion of interleukin-15 (IL-15) and the interleukin-15 receptor alpha (IL-15Rα) chain. This modification allows the DCs to "transpresent" IL-15 to neighboring T cells and natural killer (NK) cells, mimicking a natural immune process that enhances the activation, survival, and effector function of these cytotoxic lymphocytes. The vaccine is primarily being investigated for the treatment of WT1-expressing malignancies, including ovarian, pancreatic, esophageal, and liver cancers.
- Other names
- WT1-targeted IL-15-transpresenting dendritic cell vaccineWT-1-targeted IL-15-transpresenting dendritic cell vaccineWT 1-targeted IL-15-transpresenting dendritic cell vaccineIL-15-transpresenting DC vaccineIL15-transpresenting DC vaccineIL 15-transpresenting DC vaccineWT1-IL15-DC vaccineWT-1-IL15-DC vaccineWT 1-IL15-DC vaccine
02
Targets
IL2RB (IL-2 receptor beta chain)WT1-MHC (Wilms tumor protein 1 peptide presented by MHC)
Beyond the preview
Go deeper on interleukin-15-transpresenting Wilms tumor 1-targeting dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-15-transpresenting Wilms tumor 1-targeting dendritic cell vaccine.